Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Shareholders held by cbdMD, Inc. on April 10, 2025. The filing details the voting results for four key proposals regarding corporate governance, auditor ratification, capital structure amendments, and potential stock consolidation.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes and Voting Results
Shareholders approved four major proposals at the meeting. A quorum was established with 43.55% of common stock and 78.66% of Series A Preferred Stock represented.
- Proposal 1 (Director Elections): All seven nominees (Bakari Sellers, William F. Raines III, Scott G. Stephen, Dr. Sybil Swift, T. Ronan Kennedy, Jeffrey Porter, and Kevin Roe) were elected to the Board of Directors.
- Proposal 2 (Auditor Ratification): Shareholders ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2025.
- Proposal 3 (Series A Conversion): Shareholders approved an amendment to the Certificate of Designation for the 8% Series A Cumulative Convertible Preferred Stock. Each share of Series A will automatically convert into 13 shares of common stock upon the effective time of the amendment.
- Proposal 4 (Reverse Stock Split Authorization): Shareholders granted the Board of Directors the discretion to effect a reverse stock split of common stock at a ratio ranging from 1-for-3 to 1-for-10 at any time within one year of the meeting. The exact ratio will be determined by the Board.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard implications of the approved proposals. The approval of the reverse stock split authorization indicates management's intent to potentially adjust the share count to meet listing requirements or improve market perception, though the specific timing and ratio remain undetermined.
Investor Verification Checklist
- Verify the effective date of the Series A Preferred Stock conversion into common stock (13:1 ratio).
- Monitor future Board announcements regarding the specific ratio and timing of the authorized reverse stock split (1:3 to 1:10).
- Review the definitive proxy statement (Schedule 14A filed February 25, 2025) for detailed biographies of the newly elected directors.
- Confirm the impact of the Series A conversion on the total outstanding share count and potential dilution.